top of page
CPGs graded Strong
Morton CA, Birnie AJ, Eedy DJ (2013). British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease). https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjd.12766
 
Nathan P, Cohen V, Coupland S et al. (2015). Uveal Melanoma UK National Guidelines.European Journal of Cancer. 
https://www.ejcancer.com/article/S0959-8049(15)00692-9/pdf
​
Acland et al. (2014). LCA Skin Cancer: Clinical Guidelines. 
http://www.londoncanceralliance.nhs.uk/media/74850/LCA_SkinClinicalGuidelines_FINAL.pdf
​
Thomson P, Wade M (2014). Guidelines for the Management of Basal Cell Carcinoma. http://londoncancer.org/media/76370/london-cancer-bcc-guidelines-2013-v1.0.pdf
​
Queirolo P, Spagnolo F, Bassetto F et al. (2017). Linee guida Tumori cutanei non melanoma - carcinoma basocellulare (Guidelines for Non-melanoma cutaneous tumours - carcinoma basal cellular). 
http://media.aiom.it/userfiles/files/doc/LG/2017_LGAIOM_Carcinoma_basocellulare.pdf
CPGs graded Moderate
Breuninger H, Eigentler T, Bootz F et al. (2013). S2k-Leitlinie 032/022: Plattenepithelkarzinom der Haut (Brief S2k guidelines – Cutaneous squamous cell carcinoma). Dermatologic Cooperative Oncology Group (DECOG) of the German Cancer Society (DKG) and the German Society of Dermatology (DDG). J Dtsch Dermatol Ges. 2013 Jun;11 Suppl 3:37-45, 39-47. doi: 10.1111/ddg.12015_7.
hthttps://www.awmf.org/uploads/tx_szleitlinien/032-022l_S2k_Plattenepithelkarzinom_2013-abgelaufen.pdf
​
Becker JC, Assaf C, Vordermark D et al. (2013). S2k - Leitlinie - Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) – Update 2018 (S2k-Guideline Merkel Cell Carcinoma (MCC, Neuroendocrine Carcinoma of the Skin) – Update 2018). https://www.awmf.org/uploads/tx_szleitlinien/032-023l_S2k_Merkelzellkarzinom_2018-12.pdf
​
Saiag PGrob JJLebbe C et al. (2015). Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015 Nov;51(17):2604-8. doi: 10.1016/j.ejca.2015.06.108. 
https://www.eado.org/medias/Content/Files/2015-Saiag-EurGuidelineDFSP-EJC.pdf
​
Lebbe CBecker JCGrob JJ et al. (2015). Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015 Nov;51(16):2396-403. doi: 10.1016/j.ejca.2015.06.131.
https://www.eado.org/medias/Content/Files/2015-Lebbe-EurGuidelineMCC-EJC.pdf
​
Boccara O, Girard C et al. (2012). Guidelines for the diagnosis and treatment of Merkel cell carcinoma - Cutaneous Oncology Group of the French Society of Dermatology.Eur J Dermatol. 2012 May-Jun;22(3):375-9. doi: 10.1684/ejd.2012.1694.
https://www.oncopaca.org/sites/default/files/2011_reco_pec_carcinome_cellules_merkel_sfd_pro.pdf
​
Newlands, C., Currie, R., Memon, A.,  et al. (2016). Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. The Journal of laryngology and otology, 130(S2), S125–S132. doi:10.1017/S0022215116000554. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873942/pdf/S0022215116000554a.pdf
​
Unbenannt.JPG

Work Package 6

_project_management_standards.jpg

Tasks of work package 6

​

  • Map available clinical practice guidelines (CPGs) at the European level on all families of rare cancers and identify gaps

  • Quality evaluation of existing guidelines for rare cancer subtypes  

​

The JARC Work Package 6 maintains this website to share the results of quality evaluation of existing CPGs at European local and national level on rare cancers with partners involved in the EU JARC Project. However, the JARC Work Package 6 does not accept any responsibility or obligation of any kind whatsoever with regard to the information contained on this site.

The  JARC WP 6 Website contains links to other websites.

Not having control over the content of these third-party websites, no responsibility is assumed for their policies or practices.

Therefore, please review the privacy policies of these third-party websites.

Tasks of work package 6

​​

  • Open issues about implementation of CPGs at the local level and their interface with reimbursement systems

  • Work out solutions on how to assess the implementation of CPGs in the context of ERNs and national clinical collaborative networks

bottom of page